Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-2pzkn Total loading time: 0 Render date: 2024-05-15T10:21:58.741Z Has data issue: false hasContentIssue false

183 - Psychotropic Drugs and Medication

from Section 3 - Treatment and Care

Published online by Cambridge University Press:  05 June 2019

By
Andrew Scholey ,
Edward Ogden  and
Andy Parrott
Edited by
Carrie D. Llewellyn ,
Susan Ayers ,
Chris McManus ,
Stanton Newman ,
Keith J. Petrie ,
Tracey A. Revenson  and
John Weinman
Carrie D. Llewellyn
Affiliation:
University of Sussex
Susan Ayers
Affiliation:
City, University of London
Chris McManus
Affiliation:
University College London
Stanton Newman
Affiliation:
City, University of London
Keith J. Petrie
Affiliation:
University of Auckland
Tracey A. Revenson
Affiliation:
City University of New York
John Weinman
Affiliation:
King's College London
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Cambridge Handbook of Psychology, Health and Medicine , pp. 653 - 655
Publisher: Cambridge University Press
Print publication year: 2019

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Baldwin, D. S., Aitchison, K., Bateson, A., et al. (2014). Benzodiazepines: risks and benefits. A reconsideration. Focus, 12(2): 229–234.CrossRefGoogle Scholar
Barker, M. J., Greenwood, K. M., Jackson, M. & Crowe, S. F. (2004). Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis. Archives of Clinical Neuropsychology, 19(3): 437–454.CrossRefGoogle ScholarPubMed
CMO. (2016). UK Chief Medical Officers’ low risk drinking guidelines. www.gov.uk/government/uploads/system/uploads/attachment_data/file/545937/UK_CMOs__report.pdf.Google Scholar
Cohen, P. J. (2009). Medical marijuana: the conflict between scientific evidence and political ideology. Part one of two. Journal of Pain and Palliative Care Pharmacotherapy, 23(1), 4–25.Google Scholar
Connor, J. P., Haber, P. S. & Hall, W. D. (2016). Alcohol use disorders. Lancet, 387(10022), 988–998.Google Scholar
Cook, J., Lloyd‐Jones, D., Ogden, E. & Bonomo, Y. (2015). Medical use of cannabis: an addiction medicine perspective. Internal Medicine Journal, 45(6), 677–680.CrossRefGoogle ScholarPubMed
Dargan, P. I., Hudson, S., Ramsey, J. & Wood, D. M. (2011). The impact of changes in UK classification of the synthetic cannabinoid receptor agonists in ‘Spice’. International Journal of Drug Policy, 22(4), 274–277.CrossRefGoogle ScholarPubMed
Ellis, P. (2004). Australian and New Zealand clinical practice guidelines for the treatment of depression. The Australian and New Zealand Journal of Psychiatry, 38(6), 389–407.Google ScholarPubMed
Gaynes, B. N., Lloyd, S. W., Lux, L., et al. (2014). Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and meta-analysis. Journal of Clinical Psychiatry, 75, 477–489.Google Scholar
Heltsley, R., Shelby, M. K., Crouch, D. J., et al. (2012). Prevalence of synthetic cannabinoids in US athletes: initial findings. Journal of Analytical Toxicology, 36(8), 588–593.Google Scholar
Insel, T. R. (2010). Rethinking schizophrenia. Nature, 468(7321), 187–193.Google Scholar
Kalkhoran, S. & Glantz, S. A. (2016). E-cigarettes and smoking cessation in real-world and clinical settings: a systematic review and meta-analysis. Lancet Respiratory Medicine, 4(2), 116–128.CrossRefGoogle ScholarPubMed
Lancaster, T., Stead, L., Silagy, C. & Sowden, A. (2000). Effectiveness of interventions to help people stop smoking: findings from the Cochrane Library. BMJ, 321(7257), 355.Google Scholar
Leucht, S., Komossa, K., Rummel-Kluge, C., et al. (2009). A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. American Journal of Psychiatry, 166(2), 152–163.Google Scholar
Mills, E. J., Wu, P., Lockhart, I., et al. (2012). Comparisons of high-dose and combination nicotine replacement therapy, varenicline, and bupropion for smoking cessation: a systematic review and multiple treatment meta-analysis. Annals of Medicine, 44(6), 588–597.CrossRefGoogle ScholarPubMed
Mortati, K., Dworetzky, B. & Devinsky, O. (2007). Marijuana: an effective antiepileptic treatment in partial epilepsy? A case report and review of the literature. Reviews in Neurological Diseases, 4(2), 103–106.Google ScholarPubMed
New, A. S. & Stanley, B. (2010). An opioid deficit in borderline personality disorder: self-cutting, substance abuse, and social dysfunction. American Journal of Psychiatry, 167(8), 882–885.Google Scholar
Ogawa, Y., Tajika, A., Takeshima, N., Hayasaka, Y. & Furukawa, T. A. (2014). Mood stabilizers and antipsychotics for acute mania: a systematic review and meta-analysis of combination/augmentation therapy versus monotherapy. CNS drugs, 28(11), 989–1003.CrossRefGoogle Scholar
Pariente, A., de Gage, S. B., Moore, N. & Bégaud, B. (2016). The benzodiazepine–dementia disorders link: current state of knowledge. CNS drugs, 30(1), 1–7.CrossRefGoogle ScholarPubMed
Parrott, A. C. (2013). Human psychobiology of MDMA or ‘Ecstasy’: an overview of 25 years of empirical research. Human Psychopharmacology: Clinical and Experimental, 28(4): 289–307.CrossRefGoogle ScholarPubMed
Parrott, A. C. (2014). The potential dangers of using MDMA for psychotherapy. Journal of Psychoactive Drugs, 46(1), 37–43.Google Scholar
Parrott, A. C. & Murphy, R. S. (2012). Explaining the stress‐inducing effects of nicotine to cigarette smokers. Human Psychopharmacology: Clinical and Experimental, 27(2), 150–155.CrossRefGoogle ScholarPubMed
Rosenbaum, C. D., Carreiro, S. P. & Babu, K. M. (2012). Here today, gone tomorrow… and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines. Journal of Medical Toxicology, 8(1), 15–32.CrossRefGoogle Scholar
Sachdeva, A., Choudhary, M. & Chandra, M. (2015). Alcohol withdrawal syndrome: benzodiazepines and beyond. Journal of Clinical and Diagnostic Research, 9(9), VE01.Google Scholar
Smith, G. W., Farrell, M., Bunting, B. P., Houston, J. E. & Shevlin, M. (2011). Patterns of polydrug use in Great Britain: findings from a national household population survey. Drug and Alcohol Dependence, 113(2), 222–228.CrossRefGoogle ScholarPubMed
Stead, L. F., Perera, R., Bullen, C., Mant, D. & Lancaster, T. (2008). Nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews, 11, CD000146.Google Scholar
Thompson, J., Neave, N., Moss, M., et al. (1999). Sedation: cognitive properties of sedation agents – comparison of the effects of nitrous oxide and midazolam on memory and mood. British Dental Journal, 187(10), 557–562.Google Scholar
Valente, M. J., Guedes de Pinho, P., de Lourdes Bastos, M., Carvalho, F. & Carvalho, M. (2014). Khat and synthetic cathinones: a review. Archives on Toxicology, 88(1), 15–45.Google Scholar
Walker, E., Kestler, L., Bollini, A., & Hochman, K. M. (2004). Schizophrenia: etiology and course. Annual Reviews in Psychology, 55, 401–430.CrossRefGoogle ScholarPubMed
WHO. (2016). Tobacco fact sheet. www.who.int/mediacentre/factsheets/fs339/en/.Google Scholar
Wingerchuk, D. (2004). Cannabis for medical purposes: cultivating science, weeding out the fiction. Lancet, 364(9431),315–316.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×